Transaction · 0001140361-26-019378
GYREGYRE THERAPEUTICS, INC.
Gni Group Ltd.
GNI Group Ltd., 10%, reported a transaction classified as other at GYRE THERAPEUTICS, INC. involving 458120.000000 shares. Reported holdings after the transaction were 458120.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
otherSEC transaction code J10%
- Trade date
- May 04, 2026
- Filing date
- May 07, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingmissing priceThe filing did not provide a usable price per share.
ambiguous transaction codeThe transaction code is missing or represents other activity; review the filing and footnotes.
GYRE price since this filing
Daily closing prices, with the filing date and available return windowsGYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.3%1w ago1d ago +0.0%
Returns since7d30d -25.5%90d -20.1%180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- other Code J
- Identifier
- 0001140361-26-019378 Series B Preferred Stock
- Transaction date
- May 04, 2026 Filed May 07, 2026, 12:40 AM · 3d delay
- Shares
- 458,120 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 458,120 sh Indirect · See Remarks
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score
-24 points
Compact filing score computed from stored Form 4 facts. Version v1.
Low filing signal
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
Missing facts
Read the scoring methodology- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
No officer title
Officer NoDirector No10% YesOther No
Footnotes & amended
- F1
Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the…
- F2
Effective as of May 4, 2026 (the "Effective Time"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. ("Cullgen") with Cullgen surviving as a wholly-owned subsidiary of the Iss…
- F3
Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Pe…
- F4
The Series B Preferred Stock has no expiration date.
- F5
These securities are held by GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI USA, Inc., a Delaware corporation ("GNI USA") is a wholly-owned su…
- F6
These securities are held by GNI USA. GNI Japan may be deemed for purposes of Section 16 of the Exchange Act to be the indirect beneficial owner of the securities held by GNI USA.
Related transactions
Same SEC filing0 other transactions
Recent company activity
GYRE0 recent txs